{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:29:08Z","timestamp":1761823748752},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ijrobp.2015.10.055","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T16:45:27Z","timestamp":1446309927000},"page":"272-279","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?"],"prefix":"10.1016","volume":"94","author":[{"given":"Melpomeni","family":"Kountouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Rouzaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e8le","family":"Dubouloz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Linero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Escud\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Jorcano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Miralbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.10.055_bib1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib3","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group\/american college of radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2009.01.062","article-title":"Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I\/II dose escalation study","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib9","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2007.04.076","article-title":"Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: Dose-volume analysis of a phase\u00a0II dose-escalation study","volume":"69","author":"Harsolia","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/030089160909500206","article-title":"Conformal radiotherapy of clinically localized prostate cancer: Analysis of rectal and urinary toxicity and correlation with dose-volume parameters","volume":"95","author":"Ballare","year":"2009","journal-title":"Tumori"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib12","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib13","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: Alpha\/beta = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib14","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited \u2013 an analysis of clinical results from 14 168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib15","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","article-title":"Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer","volume":"84","author":"Arcangeli","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib16","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.08.009","article-title":"A systematic review of hypofractionation for primary management of prostate cancer","volume":"68","author":"Koontz","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ijrobp.2010.12.040","article-title":"Later outcomes and alpha\/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer","volume":"82","author":"Leborgne","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2007.01.008","article-title":"What dose of external-beam radiation is high enough for prostate cancer?","volume":"68","author":"Eade","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijrobp.2010.05.057","article-title":"Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: Toxicity and outcome from a dose escalation pilot study","volume":"81","author":"Zilli","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib22","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ijrobp.2009.03.078","article-title":"Radiation dose-volume effects in radiation-induced rectal injury","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.299.8.898-c","article-title":"Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate","volume":"299","author":"Zietman","year":"2008","journal-title":"Jama"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2008.11.023","article-title":"Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: A sequential dose-escalation pilot study","volume":"75","author":"Ares","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2007.04.011","article-title":"High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial","volume":"84","author":"Hoskin","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib27","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ijrobp.2007.01.067","article-title":"Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience","volume":"68","author":"Kupelian","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib28","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1016\/j.ijrobp.2012.04.012","article-title":"Hypofractionated high-dose radiation therapy for prostate cancer: Long-term results of a multi-institutional phase II trial","volume":"84","author":"Fonteyne","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0360-3016(91)90731-I","article-title":"The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: The radiation therapy oncology group 75-06 and 77-06 experience","volume":"21","author":"Lai","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00130404-200411000-00004","article-title":"Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate","volume":"10","author":"Perez","year":"2004","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib31","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ijrobp.2008.03.011","article-title":"Does treatment duration affect outcome after radiotherapy for prostate cancer?","volume":"72","author":"D'Ambrosio","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3109\/0284186X.2010.509737","article-title":"When tumor repopulation starts? The onset time of prostate cancer during radiation therapy","volume":"49","author":"Gao","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/030089161109700109","article-title":"Image-guided stereotactic body radiation therapy for localized prostate cancer","volume":"97","author":"Kang","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1748-717X-8-118","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years","volume":"8","author":"Katz","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","article-title":"Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes","volume":"107","author":"Loblaw","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.055_bib38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: Results from a multi-institutional consortium of prospective trials","volume":"87","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615266527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615266527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T19:44:05Z","timestamp":1556567045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615266527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0360301615266527"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.055","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}